Agios制药 AGIO 深 沪
已收盘 11-14 16:00:00 美东时间
43.65
+1.110
+2.61%
华盛通- 最 高44.29
- 今 开41.89
- 成交量 84.88万股
- 最 低 41.3401
- 昨 收 42.54
- 总市值 25.36亿
- 52周最高 62.45
- 市盈率 静 3.75
- 换手率 0.00%
- 52周最低 23.415
- 委 比 -86.00%
- 总股本 5810.15万
- 历史最高 138.85
- 量 比 1.45
- 振 幅 6.93%
- 历史最低 15.77
- 每 手 1
- 风险率 7.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For October 30, 2025
Companies Reporting Before The Bell • Altria Group (NYSE:MO) is projected to re...
10-30 19:12
Agios Pharmaceuticals Q3 EPS $(1.78) Beats $(1.91) Estimate, Sales $12.880M Beat $10.417M Estimate
Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.78) per share which beat the analyst consensus estimate of $(1.91) by 7 percent. This is a 110.97 percent decrease over earnings of $16.22 per share
10-30 18:35
Agios Reports Third Quarter 2025 Financial Results and Provides Business Update
Agios Pharmaceuticals reported Q3 2025 financial results and updates, highlighting $12.9 million net revenue for PYRUKYND® (mitapivat), an increase of 44% YoY. The FDA extended the PDUFA goal date for PYRUKYND's sNDA in thalassemia to December 7, 2025, due to a request for a REMS program. The CHMP adopted a positive opinion for PYRUKYND in thalassemia, with an EC decision expected by early 2026. Topline RISE UP Phase 3 trial results in sickle cel...
10-30 10:30
Earnings Outlook For Agios Pharmaceuticals
Agios Pharmaceuticals (NASDAQ:AGIO) is gearing up to announce its quarterly ear...
10-30 03:02
华兴资本医疗与生命科技行业周报【Vol.389】
来源：华兴资本 “华兴资本医疗与生命科技行业周报”定期发布，专注从资本角度解读一周数据，并提供最新行业观察。 医疗与生命科技是华兴资本多年来关注并深耕的领域，目...
10-27 09:30
EMA十月药品审评会议：赛诺菲(SNY.US)、Insmed(INSM.US)等公司新药获上市推荐
在本周召开的会议上，欧洲药品管理局的专家小组对赛诺菲与Insmed的两款新药做出了推荐在该地区上市的积极意见。
10-17 21:29
Sanofi and Insmed among winners of EU drug recommendations this week
During a meeting this week, an expert panel of the EU drug regulator, the European Medicines Agency (EMA), has endorsed two new drugs from Sanofi (NASDAQ:SNY) and Insmed (NASDAQ:INSM) for authorizatio...
10-17 20:57
美股大行评级 | 潜在涨幅90.8%！Aris Mining获Canaccord Genuity升目标价至17美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Aris Mining"买入"评级，目标价从16.5美元升至17美元；花旗：维持Docusign"买入"评级，目标价从110美元升至115美元
09-05 09:40
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Bone Biologics (NASDAQ:BBLG) shares increased by 30.4% to $2.7 during ...
09-04 20:08
Agios Pharmaceuticals shares are trading lower after the company said the FDA extended the PDUFA goal date for PYRUKYND by three months to Dec. 7.
Agios Pharmaceuticals shares are trading lower after the company said the FDA e...
09-04 19:49
